3 Active Ingredients Maker, Artificial Leather Maker and Cardiovascular and CNS Medicines Company Stocks With a Strong Future Roadmap: Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals

API maker, synthetic leather and drug stocks give investors a way to track businesses that sit close to everyday demand in India. Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals cover an active ingredients maker, an artificial leather maker and a cardiovascular and CNS medicines company.

This list covers three API maker, synthetic leather and drug stocks with complete current figures: Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are API Maker, Synthetic Leather and Drug Stocks?

API maker, synthetic leather and drug stocks are listed companies that make active ingredients for generic drugs, produce artificial leather and synthetic fabrics for footwear and autos, and sell cardiovascular and central nervous system medicines. Their earnings depend on export orders, prescriptions and input costs.

API Maker, Synthetic Leather and Drug Stocks at a Glance

On valuation, Mayur Uniquoters trades at a P/E below the industry P/E, while Neuland Laboratories and Torrent Pharmaceuticals trade above it, which reflects the growth the market already expects. Readers comparing API maker, synthetic leather and drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in API maker, synthetic leather and drug stocks can use the coming numbers to test whether growth is holding.

Why Do API Maker, Synthetic Leather and Drug Stocks Have a Strong Roadmap in India?

API maker, synthetic leather and drug stocks have a strong roadmap in India because steady global demand for generics, wider use of synthetic leather and steady chronic care demand keep widening the market for these export focused companies.

• Generic supply. Regulated markets buy Indian ingredients.
• Synthetic leather. Footwear and autos use synthetic fabrics.
• Chronic care. Branded medicines bring repeat prescriptions.

Why Neuland Laboratories Features Among These API Maker, Synthetic Leather and Drug Stocks

Among the API maker, synthetic leather and drug stocks on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.

Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.

Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.

Why Mayur Uniquoters Features Among These API Maker, Synthetic Leather and Drug Stocks

Among the pharma and material exporters shares on this list, Mayur Uniquoters is a Rajasthan-based maker of artificial leather and synthetic fabrics used in footwear, automotive upholstery, furniture and other applications.

The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P/E of 15.7, below the industry P/E of 37.9.

Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore.

Roadmap: The company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.

What to watch: Check the volume trend in automotive and footwear customers and export sales.

Why Torrent Pharmaceuticals Features Among These API Maker, Synthetic Leather and Drug Stocks

Among the three companies on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.

Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.

In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.

Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.

Neuland Laboratories vs Mayur Uniquoters vs Torrent Pharmaceuticals on Key Financials

The table below sets the three API maker, synthetic leather and drug stocks side by side on revenue, profit and margin, using reported figures.

Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Torrent Pharmaceuticals has the largest FY26 revenue at Rs 13,886 crore, and Neuland Laboratories shows the fastest revenue growth with a 21.1% compound annual rate. A useful habit with API maker, synthetic leather and drug stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in API Maker, Synthetic Leather and Drug Stocks

Every theme carries risks that deserve a check before any decision. For these API maker, synthetic leather and drug stocks, the main points are: Long-term pharma and material exporters shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Currency moves. Export earnings move with the rupee.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter API maker, synthetic leather and drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on API Maker, Synthetic Leather and Drug Stocks

API maker, synthetic leather and drug stocks work best when investors track growth, valuation and return on equity side by side. Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals each have a clear plan to grow. Based on the 3 November 2026 close, Neuland Laboratories trades at Rs 19,424, Mayur Uniquoters at Rs 753.55 and Torrent Pharmaceuticals at Rs 4,650. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these API maker, synthetic leather and drug stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track API maker, synthetic leather and drug stocks, set price alerts and get research-backed stock ideas.

What are API maker, synthetic leather and drug stocks?

Ans. API maker, synthetic leather and drug stocks are listed companies that make active ingredients for generic drugs, produce artificial leather and synthetic fabrics for footwear and autos, and sell cardiovascular and central nervous system medicines. Their earnings depend on export orders, prescriptions and input costs. This list looks at three of them, Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.

Which API maker, synthetic leather and drug stocks are covered in this list?

Ans. This list covers Neuland Laboratories, Mayur Uniquoters and Torrent Pharmaceuticals. Based on the 3 November 2026 close, Neuland Laboratories traded at Rs 19,424, Mayur Uniquoters at Rs 753.55 and Torrent Pharmaceuticals at Rs 4,650. Their return on equity ranges from 16.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.9% to 21.1%.

Why do API maker, synthetic leather and drug stocks have a strong future roadmap in India?

Ans. API maker, synthetic leather and drug stocks have a strong roadmap in India because steady global demand for generics, wider use of synthetic leather and steady chronic care demand keep widening the market for these export focused companies. The main drivers are as follows. Generic supply. Regulated markets buy Indian ingredients. Synthetic leather. Footwear and autos use synthetic fabrics. Chronic care. Branded medicines bring repeat prescriptions. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Neuland Laboratories performed financially?

Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

How has Mayur Uniquoters performed financially?

Ans. Revenue rose from Rs 677 crore in FY22 to Rs 1,022 crore in FY26, a compound annual growth rate of 10.9%. Net profit grew from Rs 94.4 crore in FY22 to Rs 192 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 292 crore, while net profit rose 37.8% to Rs 56.1 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 3,260 crore. The stock trades at a P/E of 15.7, below the industry P/E of 37.9. Looking ahead, the company supplies automotive and footwear customers in India and overseas, and demand for synthetic leather is growing as it replaces genuine leather. A debt-free balance sheet allows it to invest in new products and capacity.

How has Torrent Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

What risks should investors check before buying API maker, synthetic leather and drug stocks?

Ans. Investors should check a few risks before buying API maker, synthetic leather and drug stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of API maker, synthetic leather and drug stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.